SCHEMBL974237

SCHEMBL974237

CCC(=O)c1[nH]c2[c]cccc2c1C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.41
HSD17B10 Q99714 3/20 0.41
MAPT P10636 5/20 0.39
HPGD P15428 4/20 0.39
HTT P42858 3/20 0.39
USP2 O75604 1/20 0.39
MAOA P21397 1/20 0.36
TSHR P16473 2/20 0.36
ALOX15 P16050 2/20 0.36
KDM4E B2RXH2 4/20 0.34
MCL1 Q07820 6/20 0.33
GAA P10253 4/20 0.33
KMT2A Q03164 4/20 0.33
MEN1 O00255 3/20 0.33
POLB P06746 1/20 0.33
RECQL P46063 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
FBP1 P09467 1/20 0.32
LMNA P02545 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5652739 0.71 AHR (0.47) ALDH1A1MAPTHPGDKDM4EPOLB
SCHEMBL1653834 0.70 ALDH1A1 (0.46) ALDH1A1HSD17B10MAPTHPGDHTT
SCHEMBL1652031 0.66 FBP1 (0.68) ALDH1A1MAPTHTTTSHRKDM4E
SCHEMBL16669006 0.66 ALDH1A1 (0.33) ALDH1A1HSD17B10
SCHEMBL10412258 0.65 HSP90AB1 (0.39) ALDH1A1HSD17B10MAPTTSHRKDM4E
SCHEMBL24196991 0.64 CNR1 (0.52) ALDH1A1HSD17B10MAPTHPGDKDM4E
SCHEMBL989057 0.60 SMN1; SMN2 (0.42) ALDH1A1MAPTHPGDTSHRALOX15
SCHEMBL2305919 0.60 ALDH1A1 (0.68) ALDH1A1HSD17B10MAPTHPGDHTT
SCHEMBL3483178 0.60 ALDH1A1 (0.40) ALDH1A1HSD17B10MAPTHPGDHTT
SCHEMBL10773472 0.60 HSP90AB1 (0.38) ALDH1A1HSD17B10MAPTTSHRKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8258134-B2 Pyridazinone glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2012-09-04 US disclosed
US-20110021570-A1 PYRIDONE GLUCOKINASE ACTIVATORS HAYNES NANCY-ELLEN 2011-01-27 US disclosed
EP-2268633-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS F. Hoffmann-La Roche AG (CH) 2011-01-05 EP disclosed
US-20090264434-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2009-10-22 US disclosed
WO-2009127544-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2009-10-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110021570-A1 PYRIDONE GLUCOKINASE ACTIVATORS GCK, PDXK, G6PD ALDH1A1 902/4885HSD17B10 837/4885MAPT 3715/4885
US-20090264434-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS GCK, GCKR, PDXK ALDH1A1 1059/4885HSD17B10 826/4885MAPT 3782/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.